Sanofi Pasteur’s injectable influenza vaccine containing two A virus strains and two B virus strains for active immunisation of adults of age 18 to 64 years was approved in 2017 by Drug Controller General of India (DCGI).
The application for the paediatric indication is under review by the DCGI. Final approval is expected by the end of month of June.
Sanofi’s quadrivalent influenza vaccine was licensed for use by the US Food and Drug Administration (FDA) in 2013. It is licensed in 26 countries.
No comments:
Post a Comment